HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles

BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. OBJECTIVES: 1. Discuss the mode of acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammons, Sarah L., Topping, Donna L., Blackwell, Kimberly L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652078/
https://www.ncbi.nlm.nih.gov/pubmed/28359238
http://dx.doi.org/10.2174/1568009617666170330120452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652078/
https://www.ncbi.nlm.nih.gov/pubmed/28359238
http://dx.doi.org/10.2174/1568009617666170330120452

Ejemplares similares